Is Johnson & Johnson (JNJ) Undervalued Following Its Latest Oncology Update?

Johnson & Johnson (JNJ) stock is under fresh scrutiny after European regulators recommended expanding TALVEY’s use in relapsed or refractory multiple myeloma, adding another data backed oncology asset to the healthcare giant’s pipeline. For investors tracking the bigger picture, Johnson & Johnson’s recent drug updates, dividend affirmation and third quarter earnings all land against a share price of US$255.56, with a year to date share price return of 23.25% and a 1 year total shareholder...